After more than five decades of trying, the drug industry is on the verge of providing effective immunizations against the respiratory syncytial virus, which has put an estimated 90,000 U.S. infants and small children in the hospital since the start of October.
Kids ages 5 to 11 will soon be able to get Pfizer's low-dose COVID vaccine. CDC director Rochelle Walensky agreed with a unanimous decision of a team of advisers that the benefits outweigh the risks.